Volifen Spray

Description:

IndicationRheumatoid arthritis, Osteoarthritis, Joint and muscular painsAdministrationApply to clean, dry skin Avoid showering/bathing until gel/solution is dry for at least 30 min Wash hands after use Avoid clothing on knees until gel/solution is dryAdult DoseTopical/Cutaneous Osteoarthritis Adult: Apply 2 g (upper extremities)/4 g (lower extremities) q6hr Not to exceed 8 g/day to any single joint of (upper) extremities; 16 g/day to any single joint of (lower extremities) Local symptomatic relief of pain and inflammation Adult: As diclofenac Na (1% gel): Apply onto affected area 3 or 4 times daily.Child DoseSafety and efficacy not establishedContraindicationContraindicated to the patients hypersensitive to any ingredient of the products. Diclofenac is also contra-indicated in asthmatic patient in whom attack with asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or by other drugs with prostaglandin synthetase inhibitor. Gel should not be used under occlusive airtight dressings.Mode of ActionDiclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. Inhibits cyclooxygenase (COX)-1 and COX-2, thereby inhibiting prostaglandin synthesis. May also inhibit neutrophil aggregation/activation, inhibit chemotaxis, decrease proinflammatory cytokine level, and alter lymphocyte activity.PrecautionIn rare instances where peptic ulceration or gastro-intestinal bleeding occurs in patients under treatment with Diclofenac. In patients with advanced age should be kept under close observation. Gel should not be allowed to come in contact with the eyes or mucus membranes, after application the hands should be washed properly and not to be taken by mouth. Lactation: Excretion in milk unknown/not recommendedSide Effect>10% Dry skin (25-27%),Rash (20-35%),Contact dermatitis (19-33%),Pain (15-26%),Paresthesia (<20%),Pruritus (52%),Exfoliation (6-24%) 1-10% Hypertension,Chest pain,Skin ulcer,Diarrhea,Dyspepsia,Alepesia,Photosensitivity,Edema,Conjunctivitis,Hematuria,AsthmaPregnancy Category NotePregnancy Published literature reports that use of NSAIDs after 30 weeks’ gestation increases the risk of premature closure of the fetal ductus arteriosus Data from observational studies regarding potential embryofetal risks of NSAID use, including diclofenac, in women in the first or second trimester of pregnancy are inconclusive Clinical considerations Avoid use of NSAIDs in pregnant women after 30 weeks’ gestation because NSAIDs can cause premature closure of the fetal ductus arteriosus Lactation Data from published literature reports with oral preparations of diclofenac indicate the presence of small amounts of diclofenac in human milk There are no data on the effects on the breastfed infant or the effects on milk productionInteractionMay increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.